TL;DR
Get self-care favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Week 43 review describes contrasting industry results: P&G and Puig reported growth, while China’s online beauty sales fell 6% in September. Regulatory changes, corporate restructuring and disruption to retail and manufacturing also shaped the week.
Beauty companies reported contrasting sales trends in Week 43 of October 2026, as P&G and Puig posted growth while online beauty sales in China fell 6% in September, according to Global Cosmetics News’ weekly review. The recap also covers regulatory proposals and deadlines, corporate changes, retail unrest in Europe and a production halt at a Ukrainian personal care manufacturer.
P&G reported 4% sales growth in fiscal Q1 2027, with its Beauty division providing stronger support, the review said. Puig reported record third-quarter sales, with make-up and Asia-Pacific contributing to its performance. Dolce & Gabbana Beauty, meanwhile, is targeting double-digit growth through international expansion. These company results and ambitions sit alongside a weaker market signal: China’s online beauty sales declined 6% in September, as multinational brands faced weaker demand and increased competition, according to the report.
Corporate activity spanned portfolio changes, investment and leadership. Unilever sold its Welly bandage brand to Forward Consumer Partners, while Solabia refocused on cosmetics and nutraceuticals after appointing Muriel Koch as CEO. Proya Cosmetics opened a European innovation laboratory in France. The review also cited board and executive changes at dsm-firmenich, Chanel, Dermalogica and L’Oréal. Beyond beauty-focused companies, THG raised its 2026 profit forecast, Walmart targeted a US$6.5 billion bond sale, Malaysia’s Big Caring Pharmacy outlined plans for a US$600 million IPO, and Getty Images filed for bankruptcy protection amid AI competition and debt restructuring.
Regulatory and operational developments added uncertainty for businesses and consumers. The UK government proposed tighter restrictions on high-risk cosmetic procedures, including limits on some treatments to qualified healthcare professionals. Indonesia extended halal certification deadlines for cosmetics and personal care products to 2028. In the United States, the FDA cleared a Phase 2 trial investigating injectable PDGF for under-eye hollows, while Kenvue updated labelling and safety documentation for a Neutrogena acne toner, confirming its classification as an over-the-counter acne treatment. Separately, unrest in France and Italy disrupted retail, and a Russian attack damaged Ukrainian manufacturer 2K, forcing it to halt production, the review reported.
Mixed Signals Across Beauty Markets
The week’s developments show why a single headline figure cannot describe the global beauty business. Growth at P&G and Puig and Dolce & Gabbana Beauty’s expansion target point to opportunities for some companies, while China’s September decline indicates demand and competition pressures in a major market. The review does not provide enough data to establish how widespread or lasting that downturn is.
For companies selling across borders, regulatory timing and compliance can affect product planning and market access. Indonesia’s extension gives businesses additional time to meet halal certification requirements, while the UK proposal could change who may perform certain procedures if adopted. Store closures and the halt in Ukrainian production also underline how unrest and conflict can interrupt sales and supply.
Neutrogena acne toner salicylic acid
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Results Amid Corporate Change
The review brings together developments from different countries and business areas over one week in October 2026; it is a roundup, not a single coordinated industry announcement. Its financial items include reported company results, a forecast change, financing plans and an IPO proposal. These are distinct developments and should not be read as evidence that the whole sector is growing or contracting at one rate.
Corporate restructuring and international investment featured alongside results. The sale of Welly, Solabia’s strategic refocus and Proya’s French laboratory illustrate changes in brand ownership, company priorities and research capacity. The review also describes partnerships and brand activity, including Maybelline New York naming Hannah El Zahed its first brand ambassador in Egypt and Virgin partnering with Wonderskin on a limited-edition lip stain.
As an affiliate, we earn on qualifying purchases.
Proposals, Plans and Open Questions
The review does not give underlying financial figures for P&G or Puig, or details on the scale and duration of China’s online sales decline. It also does not specify the planned timing or final terms of Big Caring Pharmacy’s proposed IPO or Walmart’s targeted bond sale. Targets and plans are not completed transactions, and the report provides no final outcome for these proposals.
The UK measures are described as proposed restrictions, not enacted rules; the review does not identify an implementation date or the full scope of treatments covered. It also does not specify how Indonesia’s extended deadline applies to individual products or companies. Details on the damage to 2K, the duration of its production stoppage and the effects on supply are not included. The cited review provides no direct quotations from company or government representatives.
under eye hollow treatment skincare products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Regulatory and Business Milestones Ahead
Companies will need to track the UK government’s next steps on high-risk cosmetic procedures and prepare for Indonesia’s 2028 halal certification deadline. The FDA-cleared Phase 2 investigation will proceed as a clinical trial; the review does not provide a timetable or results, and clearance to conduct a study is not evidence that a treatment is effective or approved for general use.
Investors and industry observers can look for further details on the financing and listing plans cited in the review, as well as subsequent sales updates from companies facing differing market conditions. The timing of any resumption at Ukrainian manufacturer 2K and the effects of European retail closures were not stated. Those operational developments remain open as the industry moves beyond Week 43.
professional cosmetic procedure aftercare products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What was the main sales contrast in the Week 43 review?
P&G reported 4% sales growth in fiscal Q1 2027 and Puig reported record third-quarter sales, while China’s online beauty sales fell 6% in September. The figures refer to different companies, markets and reporting periods.
What regulatory changes did the review report?
The UK government proposed tighter restrictions on some high-risk cosmetic procedures. Indonesia extended halal certification deadlines for cosmetics and personal care products to 2028. The UK measures were proposals, not confirmed rules in the review.
What happened to Ukrainian manufacturer 2K?
Global Cosmetics News reported that a Russian attack damaged the personal care manufacturer and forced it to halt production. The review did not state how long the stoppage would last or detail the impact on supply.
Did the FDA approve an injectable treatment for under-eye hollows?
No. The review says the US FDA cleared a Phase 2 clinical trial investigating injectable PDGF. Trial clearance is not the same as approval for general sale or proof of effectiveness.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
